Literature DB >> 11358419

How is it best to treat early rheumatoid arthritis patients?

J R O'Dell1.   

Abstract

During the past decade, many important changes have occurred in the treatment of rheumatoid arthritis, perhaps the most important of which has been the realization that early diagnosis and early treatment are critical. This has challenged our health-care systems to make sure that patients with early arthritis have access to the appropriate physicians. Additionally, the last decade has also seen many new treatment options become available for patients with rheumatoid arthritis. These new options have included the use of old drugs more effectively; the use of combinations of two or more disease-modifying anti-rheumatic drugs; new evidence to support the use of steroids; the resurrection of tetracyclines; the introduction of leflunomide; and, finally, the tumour necrosis factor inhibitors etanercept and infliximab. The availability of all these new options is clearly excellent news for patients with RA and their physicians. It is hoped that we will, in the next few years, better understand how most effectively to utilize these treatment options for the optimal care of our patients. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358419     DOI: 10.1053/berh.2000.0130

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  5 in total

1.  The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.

Authors:  Mathilde Benhamou; Nathalie Rincheval; Carine Roy; Violaine Foltz; Sylvie Rozenberg; Jean Sibilia; Thierry Schaeverbeke; Pierre Bourgeois; Philippe Ravaud; Bruno Fautrel
Journal:  J Rheumatol       Date:  2009-03-13       Impact factor: 4.666

2.  Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

Authors:  L B A van de Putte; R Rau; F C Breedveld; J R Kalden; M G Malaise; P L C M van Riel; M Schattenkirchner; P Emery; G R Burmester; H Zeidler; H M Moutsopoulos; K Beck; H Kupper
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

3.  Antioxidant and angiostatic effect of Spirulina platensis suspension in complete Freund's adjuvant-induced arthritis in rats.

Authors:  Eman A I Ali; Bassant M Barakat; Ranya Hassan
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

Review 4.  Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes.

Authors:  Paul Emery
Journal:  Arthritis Res       Date:  2002-04-18

Review 5.  The specialist physician's approach to rheumatoid arthritis in South Africa.

Authors:  Frederik C J Bester; Fredricka J Bosch; Barend J Jansen van Rensburg
Journal:  Korean J Intern Med       Date:  2016-02-26       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.